Active Filter(s):
Details:
The financing will be used to advance and accelerate JK07, including the planned initiation of the first Phase 2 study in HFrEF and the continuation of the ongoing Phase 1b clinical trial in heart failure with preserved ejection fraction.
Lead Product(s): JK07
Therapeutic Area: Cardiology/Vascular Diseases Product Name: JK07
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: SHENZHEN SALUBRIS PHARMACEUTICALS CO.LTD.
Deal Size: $35.0 million Upfront Cash: Undisclosed
Deal Type: Financing March 28, 2023